hope to incurable blindness
For Dry Age-Related Macular Degeneration
LBS-008 is a first-in-class oral therapy targeting Dry Age-Related Macular Degeneration (AMD) and Stargardt Disease, which are untreatable conditions that cause vision loss in adults and children, respectively.
LBS-008 is an RBP4 inhibitor that prevents the buildup of toxins in the eye that cause Dry AMD and Stargardt. The toxins are a byproduct of the eye's visual cycle, which is dependent on the presence of vitamin A (retinol). LBS-008 works by reducing the amount of circulating vitamin A, and consequently reducing vitamin A uptake into the eye, thus preventing the formation of the toxins associated with macular degeneration.
LBS-008 is the most advanced and the first graduate candidate from the US National Institutes of Health’s (NIH) highly selective Blueprint Program for Neuroscience Research. The program leveraged the resources of 15 NIH centers and $10M USD in funding to cover the development cost of LBS-008 through completion of Phase 1 clinical trials. LBS-008 has initiated its phase 3 for Stargardt disease, an inherited juvenile form of macular degeneration, and expects to initiate its phase 3 for dry age-related macular degeneration in 2022. LBS-008 has obtained Orphan Drug Designation in the United States and Europe, as well as being awarded Rare Pediatric Disease (RPD) status in the US.